ACAD
32.21
+0.33
+1.05%
AEMD
0.27
+0.01
+4.83%
APRI
1.22
0.00
0.00%
ARNA
4.65
+0.1
+2.09%
ATEC
1.35
-0.02
-1.46%
CFN
59.8
+0.03
+0.05%
CNAT
5.74
+0.4
+7.49%
CRXM
0.2
0.00
-1.00%
CYTX
0.49
+0.01
+1.69%
DXCM
62.7
+4.76
+8.22%
GNMK
13.22
+0.07
+0.49%
HALO
14.42
+0.55
+3.97%
ILMN
201.52
+4.36
+2.21%
INNV
0.23
-0.02
-9.96%
INO
8.85
+0.24
+2.79%
ISCO
0.06
0.00
-1.67%
ISIS
72.86
+1.58
+2.22%
LGND
55.96
+1.29
+2.36%
LPTN
2.97
+0.01
+0.34%
MBVX
1.17
+0.03
+2.63%
MEIP
3.72
+0.03
+0.81%
MNOV
3.58
+0.03
+0.85%
MRTX
20
+0.73
+3.79%
MSTX
0.46
-0.01
-3.17%
NBIX
33.49
+1.79
+5.65%
NUVA
46.83
+0.07
+0.15%
ONCS
0.4
0.00
-0.50%
ONVO
6.74
+0.42
+6.65%
OREX
5.57
+0.16
+2.96%
OTIC
31.82
-1.12
-3.39%
QDEL
24.68
+0.36
+1.48%
RCPT
115.93
+5.83
+5.30%
RGLS
19.42
+0.88
+4.75%
RMD
67.16
+1.92
+2.94%
SCIE
0.01
0.00
0.00%
SPHS
0.46
0.00
-1.07%
SRNE
10.61
+0.64
+6.42%
TROV
5.93
+0.13
+2.24%
VICL
1.05
+0.01
+0.48%
VOLC
17.97
+0.01
+0.03%
ZGNX
1.32
+0.04
+3.13%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

CIRM stem cell funding opens

January 9, 2015 – 6:08 pm | Edit Post

California’s stem cell agency now accepting grant applications under overhauled system.

AltheaDX and BeneChill File For IPO on Same Day

January 9, 2015 – 4:54 pm | Edit Post

AltheaDx Inc., a San Diego-based molecular diagnostics firm, joined the biotech IPO boom in late December when the company filed a preliminary prospectus with the U.S. Securities and Exchange Commission stating its plans to raise $69 million in an initial public offering.

UCSD Extension and San Diego Biotechnology Network Partner To Engage, Educate, and… — SAN DIEGO, Jan. 9, 2015 /PRNewswire-iReach/ –

January 9, 2015 – 9:16 am | Edit Post

UCSD Extension and San Diego Biotechnology Network Partner To Engage, Educate, and… — SAN DIEGO, Jan. 9, 2015 /PRNewswire-iReach/ –.

Science on Screen: Join us in Orlando on January 24

January 9, 2015 – 8:21 am | Edit Post

Sanford-Burnham’s Sheila Collins, Ph.D., will be participating in the Enzian Theater’s “Science on Screen” event on January 24 in Orlando (Maitland), Fla.

Science on Screen: Join us in Orlando on January 24

January 9, 2015 – 8:21 am | Edit Post

Sanford-Burnham’s Sheila Collins, Ph.D., will be participating in the Enzian Theater’s “Science on Screen” event on January 24 in Orlando (Maitland), Fla.

Novira Therapeutics Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco

January 9, 2015 – 6:00 am | Edit Post
Novira Therapeutics Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco

DOYLESTOWN, Pa., Jan. 9, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical stage, biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced that Christian S. Schade, chief executive officer, is scheduled to present a company update and overview at the 33rd Annual J.P. Morgan Healthcare Conference at 11:30a.m. PT on Tuesday, January 13, 2015 at the Westin St. Francis Hotel in San Francisco, CA.

About NVR 3-778

NVR 3-778 is a small molecule, direct acting antiviral, for oral administration in patients with Chronic Hepatitis B (CHB) that inhibits the HBV core or capsid protein. HBV core is a novel and promising drug target with multiple activities required for viral replication and persistence. Inhibition of HBV core protein function by NVR 3-778 offers the potential for more efficient suppression of the virus leading to improved durable viral suppression and functional cure rates.

About HBV

Hepatitis B infection presents a significant unmet medical need with an estimated 350 million people worldwide living with chronic HBV infection. A significant number of patients with chronic infection incur a higher risk of developing cirrhosis and cancer. It is estimated that 60% of hepatocellular carcinoma (liver cancer) is a direct consequence of HBV infection. Current drugs approved for the management of CHB include PEG-Interferon and nucleot(s)ides which can effectively suppress virus replication, but rarely lead to a cure.

About Novira Therapeutics

Novira Therapeutics, Inc., is a privately held biopharmaceutical company focused on discovery and development of first-in-class antiviral drugs for the treatment of chronic HBV infection (CHB), a global disease with a high level of unmet medical need. The company is employing innovative chemistry and biology technologies to discover small molecule inhibitors of the HBV core or capsid protein as well as other drugs with novel mode of action. The company’s novel antivirals will offer the potential to address the limitations of current CHB therapies when used either as mono-therapy or in combination with existing standards of care.

For more information, visit www.noviratherapeutics.com.

The Novira Therapeutics name and logo are trademarks of Novira Therapeutics, Inc. or its affiliates.  All other trademarks referenced herein are owned by their respective owners.

Contacts:

Corporate Contact
Christian S. Schade
Chief Executive Officer
cschade@noviratherapeutics.com

Media Contacts
David Schull
Matt Middleman, M.D.
Russo Partners
T: (212) 845-4271
T: (212) 845-4272
david.schull@russopartnersllc.com 
matt.middleman@russopartnersllc.com

SOURCE Novira Therapeutics, Inc.

DiaCarta, Inc Closes $8 Million Series A Round for Development and Commercialization of Precision Molecular Diagnostics

January 9, 2015 – 3:50 am | Edit Post
DiaCarta, Inc Closes $8 Million Series A Round for Development and Commercialization of Precision Molecular Diagnostics

HAYWARD, California and SHANGHAI, Jan. 9, 2015 /PRNewswire/ — DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

DiaCarta has CE/IVD assays for highly sensitive mutation detection in EGFR, KRAS, NRAS, BRAF, PIK3CA and JAK-2. QClamp mutation detection assays utilize a novel xeno-nucleic acid (XNA) clamping technology to suppress amplification of wild-type DNA allowing selective amplification of mutant DNAs in real-time PCR. Mutant DNAs present at less than 0.1% can be detected. The sensitivity and specificity of QClamp make it superior to NGS and ddPCR.

DiaCarta’s QuantiVirus® HPV E6/E7 mRNA tests detect HPV E6/E7 mRNA in cervical and oral cancer. Assays are based on branched DNA signal amplification technology, performed without RNA purification or RT-PCR and do not require a clean room environment. Assays are CFDA (Chinese FDA) and CE/IVD cleared.

“We look forward to supporting the parallel development of precision molecular diagnostic tests in the US and China. These novel technologies offer an attractive option to address the growing needs of personalized medicine and companion diagnostics.” said Zhi Yang, general partner at BVCF.

“We seek to be at the forefront in the development of non-invasive tests for detection and monitoring of tumor mutations in human body fluids. We look forward to expanding our product offerings and seeking regulatory approvals in the EU, China and eventually the US.” said Aiguo Zhang, Ph.D., President & CEO of DiaCarta, Inc.

About BVCF
BVCF (http://bvcf.com/, formally known as BioVeda China Fund) is a growth capital focused private equity fund specializing in China Life Sciences and Healthcare industry. Headquartered in Shanghai, BVCF primarily focuses on equity investments in growth-stage companies in the field of Pharmaceuticals, Biotechnology, Traditional Chinese Medicine, Medical Devices, Healthcare Services, Industrial and Environmental Biotechnology. 

About DiaCarta, Inc.
DiaCarta is a leading Translational Genomics and Molecular Diagnostics company located in the San Francisco Bay area, pioneering novel molecular diagnostics technologies.

 

SOURCE DiaCarta, Inc.

Arena Pharmaceuticals, Inc. Reports On Eisai Inc.’s New Marketing Initiatives For BELVIQ?? (lorcaserin HCl) CIV

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 9, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today reported on Eisai Inc.’s updated BELVIQ marketing program with targeted new initiatives to address payers, patients and physicians.Encouraged by the increasing number of payers who have made the decision to…

Celladon Corporation Reports Inducement Grants Under Listing Rule 5635(c)(4)

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 9, 2015 (GLOBE NEWSWIRE) — Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that on January 5, 2015 the Compensation Committee of the Company’s Board of Directors…

Adamis Pharmaceuticals Announces Proposed Public Offering Of Common Stock

January 8, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical…